Summary
The clinical course, serological changes and the development of the specific cell-mediated immune response to Epstein-Barr-Virus (EBV), measured in terms of leukocyte migration inhibition, were followed in 40 children suffering from an EBV infection. The patients were followed for between six and 24 months. Although the majority of the children were under six years of age, they presented a typical clinical course; heterophil antibodies could only be demonstrated in 60% of the cases. Anti-VCA-IgM and IgG antibodies were found in all patients during the acute phase, but no anti-EBNA could be demonstrated. In children under three years of age, no antibodies against the D component of the early antigen were found; this antibody was found in 50% of the adolescents. An antibody against the R component of the early antigen could be demonstrated in 73% of the children five to six months after the onset of the disease. Specific leukocyte migration inhibition was present only during convalescence or later. A relationship between the appearance of anti-EBNA and the development of specific leukocyte migration inhibition has been established.
Zusammenfassung
Bei 40 Kindern, die eine akute Epstein-Barr-Virus (EBV)-Infektion durchmachten, wurden der klinische Verlauf, serologische Veränderungen und die Entwicklung der für EBV spezifischen zellvermittelten Immunantwort, gemessen mittels der Leukozyten-Migrations-Hemmung, über sechs bis 24 Monate verfolgt. Obwohl die Mehrzahl der Kinder jünger als sechs Jahre war ließ sich ein typischer klinischer Verlauf feststellen; nur bei 60% der Fälle waren heterophile Antikörper nachweisbar. Während der akuten Krankheitsphase fanden sich bei allen Patienten anti-VCA-IgM und IgG Antikörper, anti-EBNA ließ sich nicht nachweisen. Antikörper gegen die D-Komponente des frühen Antigens waren bei Kindern unter drei Jahren nie zu finden, bei Adoleszenten hingegen in 50% der Fälle. Fünf bis sechs Monate nach Krankheitsbeginn zeigte sich bei 73% der Kinder ein Antikörper gegen die R-Komponente des frühen Antigens. Eine spezifische Leukozyten-Migrationshemmung war nur in der Rekonvaleszenzphase oder später vorhanden. Zwischen dem Erscheinen von anti-EBNA und dem Auftreten einer spezifischen Leukozyten-Migrationshemmung ließ sich eine Beziehung herstellen.
Similar content being viewed by others
Literature
Henle, C., Henle, W. The virus as the etiologic agent of infectious mononucleosis. In:Epstein, M. A., Achong, G. B. (eds.): The Epstein-Barr virus. Springer, New York 1979, p. 297.
Andiman, W. A. The Epstein-Barr virus and EB virus infections in childhood. J. Pediatr. 95 (1979) 171–182.
Rapp, C. E., Hewetson, J. F. Infectious mononucleosis and the Epstein-Barr virus. Am. J. Dis. Child. 132 (1978) 78–86.
Biggar, R. J., Henle, G., Böcker, J., Lennette, E. T., Fleisher, G., Henle, W. Primary Epstein-Barr virus infections in African infants. II. Clinical and serological observations during seroconversion. Int. J. Cancer 22 (1978) 244–250.
Fleisher, G., Henle, W., Henle, G., Lennette, E. T., Biggar, R. J. Primary infection with Epstein-Barr virus in infants in the United States: clinical and serologic observations. J. Infect. Dis. 139 (1979) 553–558.
Purtilo, D. T.: Immunopathology of infectious mononucleosis and other complications of Epstein-Barr virus infections. Pathology Annual (in print).
Lai, P. K., Alpers, M. P. Cell-mediated immune responses in man to Epstein-Barr (EB) virus infection. Comp. Immun. Microbiol. Infect. Dis. 2 (1980) 565–585.
Thestrup-Pederson, K., Esman, V., Bisballe S., Jensen, J. R., Pallesen, G., Hastrup, J., Madsen, M., Thorling, K., Grazia-Masucci, M., Saemundsen, A. K., Ernberg. I. Epstein-Barr-virus-induced lymphoproliferalive disorder converting to fatal Burkittlike lymphoma in a boy with interferon-inducible chromosomal defect. Lancet II (1980) 997–1002.
Purtilo, D. T. Epstein-Barr virus induced oncogenesis in immunedeficient individuals. Lancet I (1980) 300–304.
Nagington, J., Gray, J. Cyclosporin-A immunosuppression, Epstein-Barr antibody, and lymphoma. Lancet I (1980) 536–537.
Crawford, D. H., Seveny, P., Edvards, J. M. B., Janossy, G., Hoffbrand, A. V. Long-term T-cell-mediated immunity to Epstein-Barr virus in renal-allograft recipients receiving cyclosporin A. Lancet I (1981) 10–12.
Robinson, J. E., Brown, N., Andiman, W., Holliday, K., Francke, U., Robert, M. F., Andersson-Anvret, M., Horstmann, D., Miller, G. Diffuse polyclonal B-cell lymphoma during primary infection with Epstein-Barr virus. N. Engl. J. Med. 302 (1980) 1293–1297.
Schmitz, H., Volz, D., Krainick-Riechert, C., Scherer, M. Acute Epstein-Barr virus infections in children. Med. Microbiol. Immunol. 158 (1972) 58–63.
Tamir, D., Benderly, A., Levi, J., Ben-Porath, E., Vonsover, A. Infectious mononucleosis and Epstein-Barr virus in childhood. Pediatrics 53 (1974) 330–335.
Nikoskelainen, J., Leikola, J., Klemola, E. IgM antibodies specific for Epstein-Barr virus in infectious mononucleosis without heterophil antibodies. Br. Med. J. 4 (1974) 72–75.
Sumaya, C. V. Primary Epstein-Barr virus infections in children. Pediatrics 59 (1977) 16–21.
Ginsburg, C. M., Henle, W., Henle, G., Horwitz, C. A. Infectious mononucleosis in children. J. Am. Med. Assoc. 237 (1977) 781–788.
Peller, P., Goetz, I. Die Diagnose von Epstein-Barr-Virus-Infektionen mit dem IgM-Immunfluoreszenztest. Monatschr. Kinderheilk. 127 (1979) 728–731.
Fleischer, G., Lennette, E. T., Henle, G., Henle, W. Incidence of heterophil antibody responses in children with infectious mononucleosis. J. Pediatr. 94 (1979) 723–728.
Takiuchi, Y., Tatsumi, E., Shirakawa, S., Uchino, H. Infectious mononucleosis and Epstein-Barr virus in Japan. I. Clinical and serological aspects. Acta Haematol. Japan 43 (1980) 700–710.
Timár, L., Koller, M., Budai, J. Serological follow-up of children with infectious mononucleosis caused by the Epstein-Barr virus. Acta Paediatr. Acad. Sci. Hung. 22 (1981) 243–249.
Szigeti, R., Timár, L., Révész, T. Leukocyte migration inhibition with Epstein-Barr virus negative and positive cell extracts. Allergy 35 (1980) 97–103.
Wainwright, W. H., Veltri, R. W., Sprinkle, P. M. Abrogation of cell-mediated immunity by a serum blocking factor isolated from patients with infectious mononucleosis. J. Infect. Dis. 140 (1979) 22–32.
Pollowitz, J. A. Infectious mononucleosis. Am. J. Dis. Child. 132 (1978) 819.
Svedmyr, E., Jondal, M. Cytotoxic effector cells specific for B cell lines transformed by Epstein-Barr virus are present in patients with infectious mononucleosis. Proc. Nat. Acad. Sci. USA 72 (1975) 1622–1626.
Royston, I., Sullivan, J. L., Periman, P. O., Perkins, E. Cellmediated immunity to Epstein-Barr-virus-transformed lymphoblastoid cells in acute infectious mononucleosis. N. Engl. J. Med. 293 (1975) 1159–1163.
De Waele, M., Thielemans, C., Van Camp, B. K. G. Characterization of immune regulatory T cells in EBV-induced infectious mononucleosis by monoclonal antibodies. N. Engl. J. Med. 304 (1981) 460–462.
Szigeti, R., Luka, J., Klein, G. Leukocyte migration inhibition studies with Epstein-Barr virus (EBV) determined nuclear antigen (EBNA) in relation to the EBV-carrier status of the donor. Cell. Immunol. 58 (1981) 269–276.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Timár, L., Budai, J. & Koller, M. A prospective study on infectious mononucleosis in childhood — symptoms, serology, Epstein-Barr-Virus specific leukocyte migration inhibition. Infection 10, 139–143 (1982). https://doi.org/10.1007/BF01640763
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF01640763